251.95

0.53% -1.34

After Hours: 251.93 -0.02 -0.01%

Ascendis Pharma A S (ASND)

Overview News Price History Option Chain Why ASND Down? Discussions Forecast

Ascendis Pharma A S stock is traded at $251.95, with a volume of 329.92K. It is down -0.53% in the last 24 hours and down -0.75% over the past month. Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.

Previous Close:

$253.29

Open:

$256.35

24h Volume:

329.92K

Relative Volume:

0.50

Market Cap:

$16.53B

Revenue:

$1.01B

Net Income/Loss:

$581.90M

P/E Ratio:

28.39

EPS:

8.8733

Net Cash Flow:

$50.57M

1W Performance:

+1.84%

1M Performance:

-0.75%

6M Performance:

+7.22%

1Y Performance:

+29.67%

1-Day Range:

$247.03

$256.35

1-Week Range:

$245.68

$261.61

52-Week Range:

$186.05

$282.15

Ascendis Pharma A S Stock (ASND) Company Profile

Name

Ascendis Pharma A S

Sector

Healthcare (1033)

Industry

Biotechnology (582)

Phone

Address

Employee

1,189

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

ASND's Discussions on Twitter

Compare ASND vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ASND Ascendis Pharma A S	251.95	16.71B	1.01B	581.90M	50.57M	8.8733
VRTX Vertex Pharmaceuticals Inc	547.59	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	828.50	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,011.11	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	138.89	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	211.58	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-16-26	Resumed	Jefferies	Buy
Jan-28-26	Initiated	Barclays	Overweight
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Oct-17-25	Initiated	Raymond James	Strong Buy
Jul-03-25	Resumed	Morgan Stanley	Overweight
May-05-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-16-25	Initiated	RBC Capital Mkts	Outperform
Jan-07-25	Initiated	UBS	Buy
Sep-05-24	Upgrade	Oppenheimer	Perform → Outperform
Jun-25-24	Upgrade	TD Cowen	Hold → Buy
May-31-24	Initiated	Stifel	Buy
Dec-20-23	Initiated	Jefferies	Buy
Jun-14-23	Resumed	Credit Suisse	Neutral
Apr-05-23	Downgrade	Oppenheimer	Outperform → Perform
Apr-04-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Apr-03-23	Downgrade	Credit Suisse	Outperform → Neutral
Oct-20-22	Initiated	Goldman	Buy
Aug-30-22	Resumed	Berenberg	Buy
Mar-28-22	Resumed	Wedbush	Outperform
Mar-15-22	Upgrade	BofA Securities	Neutral → Buy
Mar-01-22	Initiated	Citigroup	Buy
Feb-14-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-06-22	Initiated	Cowen	Market Perform
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-20-21	Downgrade	BofA Securities	Buy → Neutral
Mar-30-21	Downgrade	Oppenheimer	Outperform → Perform
Mar-11-21	Resumed	Stifel	Buy
Dec-17-20	Initiated	Berenberg	Buy
Sep-14-20	Resumed	JP Morgan	Overweight
Mar-20-20	Initiated	Oppenheimer	Outperform
Oct-11-19	Initiated	Morgan Stanley	Overweight
Mar-25-19	Initiated	Evercore ISI	Outperform
Jan-24-19	Initiated	Cantor Fitzgerald	Overweight
Jan-24-19	Upgrade	Leerink Partners	Mkt Perform → Outperform
Jun-26-18	Initiated	Stifel	Buy
Apr-02-18	Reiterated	Leerink Partners	Mkt Perform
May-11-17	Initiated	JP Morgan	Overweight
Mar-09-17	Downgrade	Leerink Partners	Outperform → Mkt Perform
Feb-09-17	Initiated	Credit Suisse	Outperform
Sep-26-16	Initiated	Wedbush	Outperform

View All

Ascendis Pharma A S Stock (ASND) Latest News

Aug 21, 2026

Ascendis Pharma (ASND): Three New Drugs Are Turning This Biotech Into A Growth Machine - Yahoo Finance

Aug 21, 2026

Aug 20, 2026

Ascendis Pharma (ASND) Q2 2026 Earnings Call Transcript - AOL.com

Aug 20, 2026

Is Ascendis Pharma (ASND) Priced Too Richly After Recent Progress? - Yahoo Finance

Aug 20, 2026

Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to Strong-Buy at BMO Capital Markets - MarketBeat

Aug 20, 2026

Ascendis Pharma (ASND) Reports Earnings And Trial Updates, Is It Fully Priced? - Yahoo Finance

Aug 20, 2026

Price to earnings forward of Ascendis Pharma A/S – NASDAQ:ASND - TradingView

Aug 20, 2026

Aug 19, 2026

Ascendis a new outperform at BMO on TransCon platform growth - Seeking Alpha

Aug 19, 2026

Penn Series Small Cap Growth Fund's Ascendis Pharma AS(ASND) Holding History - GuruFocus

Aug 19, 2026

BMO initiates Ascendis Pharma stock coverage with outperform rating By Investing.com - Investing.com Nigeria

Aug 19, 2026

BMO initiates Ascendis Pharma stock coverage with outperform rating - Investing.com

Aug 19, 2026

BMO Capital Initiates Ascendis Pharma at Outperform - marketscreener.com

Aug 19, 2026

Ascendis Pharma (ASND) Reports Positive Phase 2 Achondroplasia Data As Pivotal Trial Enrollment Ends - Sahm

Aug 19, 2026

Why Is Nasdaq Watching Ascendis Pharma (NASDAQ:ASND) Endocrine Drugs? - Kalkine Media

Aug 19, 2026

Aug 18, 2026

Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime Purchases 2,000 Shares of Stock - MarketBeat

Aug 18, 2026

Ascendis Pharma (NASDAQ: ASND) director adds 2,000 shares - Stock Titan

Aug 18, 2026

Ascendis Pharma director Jean-Jacques Bienaime buys USD 492,079 of common shares - Bitget

Aug 18, 2026

Aug 17, 2026